

1. [Novartis copy of Amgen arthritis drug highly similar: FDA staff](#) – Reuters

Novartis AG's cheaper version of Amgen Inc's blockbuster arthritis drug Enbrel is highly similar in potency and safety to the original, according to a review by Food and Drug Administration staff.

The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of outside advisers who will discuss the drug and recommend whether it should be approved. The FDA is not obliged to follow the recommendations of its advisory panels but typically does so.

1. [Novartis copy of Amgen arthritis drug highly similar: FDA staff](#) – Reuters
2. [Sun Pharma starts rollout of Gemcitabine InfuSMART in six European nations](#) – The Economic Times
3. [Sun Pharma will be unstoppable if it integrates Ranbaxy well: Amit Rajan, Director, Celogen Life Science](#) – The Economic Times
4. [India, Russia discuss ways to boost trade ties](#)- The Economic Times
5. [Discovery of ovarian cancer target paves way for new treatment](#) – The Times of India
6. [Trivitron Healthcare buys majority stake in Bome Sanayi](#) – The Times of India
7. [DoP asks NPPA to re-fix ceiling price of 'Clotrimazole Cream 1%' on review petition filed by Glenmark](#) – Pharmabiz.com
8. [Indian Pharma market clocks lowest growth of 6.4% in June 2016](#) – Pharmabiz.com

2. [Sun Pharma starts rollout of Gemcitabine InfuSMART in six European nations](#) – The Economic Times

India's largest drug maker Sun PharmaBSE 1.41 % announced today it commenced rollout of InfuSMART, what it claimed is the world's first ready-to-administer versions of anti-cancer drug gemcitabine in six European countries including Netherlands, UK, Spain, Germany, Italy and France.

The company said the product that will be available in a bag, is part of its business strategy to build a "meaningful and differentiating presence in the global oncology therapy market." Gemcitabine is indicated in the treatment of ovarian, lung, breast and pancreatic cancer.

3. [Sun Pharma will be unstoppable if it integrates Ranbaxy well: Amit Rajan, Director, Celogen Life Science](#) – The Economic Times

In this interview with ET Now, Amit Rajan, Director, Celogen Life Science talks about Indian pharma companies and US FDA process. "If I summarise the pharma story in India for the last 10 years, it is like rise, fall and a very big rise. One sector which has always been defensive in terms of investment in India is pharma sector. You will not hear the story of FDA getting into data integrity issues in big pharma at all. Big pharma is ready to take on the generic story further. This rise is very robust as they have all learned the lessons," he said.

4. [India, Russia discuss ways to boost trade ties](#)- The Economic Times

Commerce and Industry Minister Nirmala Sitharaman met her Russian counterpart Denis Manturov and discussed ways to enhance bilateral trade ties in various sectors, including high-end engineering.

Noting that India has relaxed FDI norms in segments like defence, civil aviation, pharmaceuticals and food products, Sitharaman invited Russian entities to partner with the country so that the

two nations "can play a major role in reviving global growth", Engineering Exports Promotion Council (EEPC) quoted the minister in a statement.

5. [Discovery of ovarian cancer target paves way for new treatment](#) – The Times of India  
A team of researchers has brought fresh hope in the form of a new treatment target for [ovarian cancer](#) aka "the silent killer." Researchers at [Cold Spring Harbor Laboratory](#) arrived at "new insights into signalling events that underlie metastasis in ovarian [cancer cells](#)," said researcher Gaofeng Fan.

"The statistics point to the urgent need to address advanced disease - metastasis - in ovarian cancer," Fan noted, adding "The problem is especially difficult because of a feature specific to this form of cancer: ovarian cells move around readily within the peritoneal cavity, via the peritoneal fluid, both under normal conditions, and also, unfortunately, when cancer is present.

6. [Trivitron Healthcare buys majority stake in Bome Sanayi](#) – The Times of India  
Chennai-based medical device maker Trivitron Healthcare on Monday said it has bought 60% stake in Turkish healthcare firm Bome Sanayi Urunleri Dis Tic Ltd Sti for 5 million euros (Rs 37.10 crore).  
The remaining 40% stake in the in-vitro diagnostic (IVD) device maker will be held by its promoters. With the latest addition, Trivitron will now have nine manufacturing facilities in India, Finland and Turkey.

"Bome has a majority share of the new born screening tests' market. They screen more than 1.8 million babies and conduct 10 million tests a year. So with this acquisition, we'll have access to Bome's production facility, research labs and new born screening lab," said GSK Velu, chairman and managing director, Trivitron.

7. [DoP asks NPPA to re-fix ceiling price of 'Clotrimazole Cream 1%' on review petition filed by Glenmark](#) – Pharmabiz.com

The Department of Pharmaceuticals (DoP) has directed the National Pharmaceutical Pricing Authority (NPPA) to re-fix the ceiling price of "Clotrimazole Cream 1%" within a period of one month. The NPPA through its notification No. S.O. 1687(E) dated 09/05/2016 issued under Drugs (Prices Control) Order, 2013 (DPCO 2013) had fixed the price of "Clotrimazole 1% Cream".

Aggrieved by the notification, Glenmark Pharmaceuticals submitted a review application under paragraph 31 of the DPCO 2013 dated 07.06.2016 against price fixation of "Clotrimazole 1% Cream" vide NPPA order No. S.O. 1687(E) dated 09/05/2016 issued under DPCO 2013.

In the review petition, the petitioner contended that full due diligence had not been done to capture data of all brands to calculate the ceiling prices. List of formulations that should have been considered in the first place and have been totally missed in the working sheet while arriving at the ceiling price of Clotrimazole 1% Cream.

8. [Indian Pharma market clocks lowest growth of 6.4% in June 2016](#) – Pharmabiz.com  
The Indian Pharmaceutical Market (IPM) has clocked a growth of 6.4 per cent only during June 2016 which touched to Rs.8,460 crore as against Rs.7,954 crore in the last month according to AIOCD AWACS report. Market has added Rs.507 crore over last year, whereas last year the market had added Rs.1,025 crore. The current growth rate was lowest during last one year and was impacted by fixed-dose combination (FDCs), NLEM and season impact. IPM grabbed strong growth of 14.8 per cent in June quarter of last year and it touched to its lowest in third quarter of 2013 at 4.5 per cent.

Among the top 50 companies, 29 companies crossed the growth of IPM during June 2016. Mankind grew at 18.9 per cent, Macleods at 11.7 per cent followed by Alkem at 9.7 per cent. 21 companies achieved growth of more than 10 per cent. Indian companies marked growth of 7.6 per cent as against MNCs only 2 per cent in June 2016. Amongst the top 50 in MNCs, Janssen grew at 13.2 per cent followed by Allergan at 11.1 per cent and Merck at 7.5 per cent.